Related Experiment Videos
Problems with prognostic criteria in patients with chronic lymphocytic leukemia with special reference to DPP II
Insights
Detailed examinations of chronic lymphocytic leukemia (CLL) patients revealed dipeptidylaminopeptidase II (DPP II) levels may predict disease progression. Biochemical and immunological markers did not correlate with prognosis in this study.
Area of Science:
- Hematology
- Oncology
- Clinical Immunology
Background:
- Chronic lymphocytic leukemia (CLL) is a common lymphoid malignancy.
- Accurate prognostic markers are crucial for managing CLL patients.
- Current staging systems, like Rai, have limitations in predicting disease course.
Purpose of the Study:
- To investigate if detailed clinical, biochemical, immunological, and cytochemical analyses can subclassify CLL for prognostic purposes.
- To evaluate the prognostic significance of dipeptidylaminopeptidase II (DPP II) in CLL.
- To assess the limitations of the Rai staging system in CLL prognosis.
Main Methods:
- Prospective study of 106 consecutive CLL patients.
- Comprehensive clinical, biochemical, and immunological assessments.
- Cytochemical analysis, specifically focusing on dipeptidylaminopeptidase II (DPP II) expression on lymphocytes.
Main Results:
- No correlation was found between biochemical or immunological parameters and clinical stage (Rai) or disease evolution.
- Cytochemical examination revealed that DPP II positivity in lymphocytes may have prognostic value.
- Patients with stable CLL exhibited significantly lower DPP II-positive lymphocytes compared to those with progressive disease.
Conclusions:
- DPP II expression on lymphocytes shows potential as a prognostic marker in CLL.
- Biochemical and immunological markers studied do not appear to be reliable prognostic indicators for CLL.
- The Rai staging system's prognostic significance in CLL may be limited, highlighting the need for complementary markers.
Abstract:
106 consecutive patients with chronic lymphocytic leukemia (CLL) were entered into prospective study with the aims of finding out whether a detailed clinical, biochemical, immunological and cytochemical examination might help to subclassify CLL with respect to prognosis. None of the biochemical and immunological parameters studied correlated either with the clinical stage of the disease according to Rai, or with further evolution of the disease. On the other hand, the results of cytochemical tests indicated that the reaction for DPP II (dipeptidylaminopeptidase) might be of prognostic value, because in patients with stable disease, significantly lower number of DPP II positive lymphocytes were found when compared with patients suffering from progressive disease. The authors also point out some short-comings of Rai's staging system in respect to its prognostic significance.